Cancer-associated stroke: Pathophysiology, detection and management (Review)

Efthimios Dardiotis, Athina Maria Aloizou, Sofia Markoula, Vasileios Siokas, Konstantinos Tsarouhas, Georgios Tzanakakis, Massimo Libra, Athanassios P. Kyritsis, Alexandros G. Brotis, Michael Aschner, Illana Gozes, Dimitrios P. Bogdanos, Demetrios A. Spandidos, Panayiotis D. Mitsias, Aristidis Tsatsakis

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in cancer patients is discussed, while providing vital information on the diagnosis and management of patients with cancer and stroke. Cancer may mediate stroke pathophysiology either directly or via coagulation disorders that establish a state of hypercoagulation, as well as via infections. Cancer treatment options, such as chemotherapy, radiotherapy and surgery have all been shown to aggravate the risk of stroke as well. The clinical manifestation varies greatly depending upon the underlying cause; however, in general, cancer-associated strokes tend to appear as multifocal in neuroimaging. Furthermore, several serum markers have been identified, such as high D‑Dimer levels and fibrin degradation products. Managing cancer patients with stroke is a delicate matter. The cancer should not be considered a contraindication in applying thrombolysis and recombinant tissue plasminogen activator (rTPA) administration, since the risk of hemorrhage in cancer patients has not been reported to be higher than that in the general population. Anticoagulation, on the contrary, should be carefully examined. Clinicians should weigh the benefits and risks of anticoagulation treatment for each patient individually; the new oral anticoagulants appear promising; however, low-molecular-weight heparin remains the first choice. On the whole, stroke is a serious and not a rare complication of malignancy. Clinicians should be adequately trained to handle these patients efficiently.

Original languageEnglish (US)
Pages (from-to)779-796
Number of pages18
JournalInternational Journal of Oncology
Volume54
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Stroke
Neoplasms
Fibrin Fibrinogen Degradation Products
Low Molecular Weight Heparin
Tissue Plasminogen Activator
Neuroimaging
Anticoagulants
Epidemiology
Radiotherapy
Biomarkers
Hemorrhage
Drug Therapy
Therapeutics
Infection
Population

Keywords

  • Cancer
  • Cancer-associated stroke
  • Hemorrhagic stroke
  • Ischemic stroke
  • Stroke

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dardiotis, E., Aloizou, A. M., Markoula, S., Siokas, V., Tsarouhas, K., Tzanakakis, G., ... Tsatsakis, A. (2019). Cancer-associated stroke: Pathophysiology, detection and management (Review). International Journal of Oncology, 54(3), 779-796. https://doi.org/10.3892/ijo.2019.4669

Cancer-associated stroke : Pathophysiology, detection and management (Review). / Dardiotis, Efthimios; Aloizou, Athina Maria; Markoula, Sofia; Siokas, Vasileios; Tsarouhas, Konstantinos; Tzanakakis, Georgios; Libra, Massimo; Kyritsis, Athanassios P.; Brotis, Alexandros G.; Aschner, Michael; Gozes, Illana; Bogdanos, Dimitrios P.; Spandidos, Demetrios A.; Mitsias, Panayiotis D.; Tsatsakis, Aristidis.

In: International Journal of Oncology, Vol. 54, No. 3, 01.03.2019, p. 779-796.

Research output: Contribution to journalReview article

Dardiotis, E, Aloizou, AM, Markoula, S, Siokas, V, Tsarouhas, K, Tzanakakis, G, Libra, M, Kyritsis, AP, Brotis, AG, Aschner, M, Gozes, I, Bogdanos, DP, Spandidos, DA, Mitsias, PD & Tsatsakis, A 2019, 'Cancer-associated stroke: Pathophysiology, detection and management (Review)' International Journal of Oncology, vol. 54, no. 3, pp. 779-796. https://doi.org/10.3892/ijo.2019.4669
Dardiotis E, Aloizou AM, Markoula S, Siokas V, Tsarouhas K, Tzanakakis G et al. Cancer-associated stroke: Pathophysiology, detection and management (Review). International Journal of Oncology. 2019 Mar 1;54(3):779-796. https://doi.org/10.3892/ijo.2019.4669
Dardiotis, Efthimios ; Aloizou, Athina Maria ; Markoula, Sofia ; Siokas, Vasileios ; Tsarouhas, Konstantinos ; Tzanakakis, Georgios ; Libra, Massimo ; Kyritsis, Athanassios P. ; Brotis, Alexandros G. ; Aschner, Michael ; Gozes, Illana ; Bogdanos, Dimitrios P. ; Spandidos, Demetrios A. ; Mitsias, Panayiotis D. ; Tsatsakis, Aristidis. / Cancer-associated stroke : Pathophysiology, detection and management (Review). In: International Journal of Oncology. 2019 ; Vol. 54, No. 3. pp. 779-796.
@article{f1af55e6e96d4e2f9050cf37e0ecedbd,
title = "Cancer-associated stroke: Pathophysiology, detection and management (Review)",
abstract = "Numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in cancer patients is discussed, while providing vital information on the diagnosis and management of patients with cancer and stroke. Cancer may mediate stroke pathophysiology either directly or via coagulation disorders that establish a state of hypercoagulation, as well as via infections. Cancer treatment options, such as chemotherapy, radiotherapy and surgery have all been shown to aggravate the risk of stroke as well. The clinical manifestation varies greatly depending upon the underlying cause; however, in general, cancer-associated strokes tend to appear as multifocal in neuroimaging. Furthermore, several serum markers have been identified, such as high D‑Dimer levels and fibrin degradation products. Managing cancer patients with stroke is a delicate matter. The cancer should not be considered a contraindication in applying thrombolysis and recombinant tissue plasminogen activator (rTPA) administration, since the risk of hemorrhage in cancer patients has not been reported to be higher than that in the general population. Anticoagulation, on the contrary, should be carefully examined. Clinicians should weigh the benefits and risks of anticoagulation treatment for each patient individually; the new oral anticoagulants appear promising; however, low-molecular-weight heparin remains the first choice. On the whole, stroke is a serious and not a rare complication of malignancy. Clinicians should be adequately trained to handle these patients efficiently.",
keywords = "Cancer, Cancer-associated stroke, Hemorrhagic stroke, Ischemic stroke, Stroke",
author = "Efthimios Dardiotis and Aloizou, {Athina Maria} and Sofia Markoula and Vasileios Siokas and Konstantinos Tsarouhas and Georgios Tzanakakis and Massimo Libra and Kyritsis, {Athanassios P.} and Brotis, {Alexandros G.} and Michael Aschner and Illana Gozes and Bogdanos, {Dimitrios P.} and Spandidos, {Demetrios A.} and Mitsias, {Panayiotis D.} and Aristidis Tsatsakis",
year = "2019",
month = "3",
day = "1",
doi = "10.3892/ijo.2019.4669",
language = "English (US)",
volume = "54",
pages = "779--796",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Cancer-associated stroke

T2 - Pathophysiology, detection and management (Review)

AU - Dardiotis, Efthimios

AU - Aloizou, Athina Maria

AU - Markoula, Sofia

AU - Siokas, Vasileios

AU - Tsarouhas, Konstantinos

AU - Tzanakakis, Georgios

AU - Libra, Massimo

AU - Kyritsis, Athanassios P.

AU - Brotis, Alexandros G.

AU - Aschner, Michael

AU - Gozes, Illana

AU - Bogdanos, Dimitrios P.

AU - Spandidos, Demetrios A.

AU - Mitsias, Panayiotis D.

AU - Tsatsakis, Aristidis

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in cancer patients is discussed, while providing vital information on the diagnosis and management of patients with cancer and stroke. Cancer may mediate stroke pathophysiology either directly or via coagulation disorders that establish a state of hypercoagulation, as well as via infections. Cancer treatment options, such as chemotherapy, radiotherapy and surgery have all been shown to aggravate the risk of stroke as well. The clinical manifestation varies greatly depending upon the underlying cause; however, in general, cancer-associated strokes tend to appear as multifocal in neuroimaging. Furthermore, several serum markers have been identified, such as high D‑Dimer levels and fibrin degradation products. Managing cancer patients with stroke is a delicate matter. The cancer should not be considered a contraindication in applying thrombolysis and recombinant tissue plasminogen activator (rTPA) administration, since the risk of hemorrhage in cancer patients has not been reported to be higher than that in the general population. Anticoagulation, on the contrary, should be carefully examined. Clinicians should weigh the benefits and risks of anticoagulation treatment for each patient individually; the new oral anticoagulants appear promising; however, low-molecular-weight heparin remains the first choice. On the whole, stroke is a serious and not a rare complication of malignancy. Clinicians should be adequately trained to handle these patients efficiently.

AB - Numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in cancer patients is discussed, while providing vital information on the diagnosis and management of patients with cancer and stroke. Cancer may mediate stroke pathophysiology either directly or via coagulation disorders that establish a state of hypercoagulation, as well as via infections. Cancer treatment options, such as chemotherapy, radiotherapy and surgery have all been shown to aggravate the risk of stroke as well. The clinical manifestation varies greatly depending upon the underlying cause; however, in general, cancer-associated strokes tend to appear as multifocal in neuroimaging. Furthermore, several serum markers have been identified, such as high D‑Dimer levels and fibrin degradation products. Managing cancer patients with stroke is a delicate matter. The cancer should not be considered a contraindication in applying thrombolysis and recombinant tissue plasminogen activator (rTPA) administration, since the risk of hemorrhage in cancer patients has not been reported to be higher than that in the general population. Anticoagulation, on the contrary, should be carefully examined. Clinicians should weigh the benefits and risks of anticoagulation treatment for each patient individually; the new oral anticoagulants appear promising; however, low-molecular-weight heparin remains the first choice. On the whole, stroke is a serious and not a rare complication of malignancy. Clinicians should be adequately trained to handle these patients efficiently.

KW - Cancer

KW - Cancer-associated stroke

KW - Hemorrhagic stroke

KW - Ischemic stroke

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85060574454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060574454&partnerID=8YFLogxK

U2 - 10.3892/ijo.2019.4669

DO - 10.3892/ijo.2019.4669

M3 - Review article

VL - 54

SP - 779

EP - 796

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -